Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CRNX 
Crinetics Pharmaceuticals Inc (CRNX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: CRNX (3-star) is a STRONG-BUY. BUY since 46 days. Simulated Profits (22.74%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
17 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $80.27
1 Year Target Price $80.27
| 11 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 71.73% | Avg. Invested days 52 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.01B USD | Price to earnings Ratio - | 1Y Target Price 80.27 |
Price to earnings Ratio - | 1Y Target Price 80.27 | ||
Volume (30-day avg) 17 | Beta 0.2 | 52 Weeks Range 24.10 - 62.53 | Updated Date 11/5/2025 |
52 Weeks Range 24.10 - 62.53 | Updated Date 11/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.1 |
Earnings Date
Report Date 2025-11-06 | When - | Estimate -1.25 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -12522.99% |
Management Effectiveness
Return on Assets (TTM) -23.77% | Return on Equity (TTM) -36.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2762821510 | Price to Sales(TTM) 2877.37 |
Enterprise Value 2762821510 | Price to Sales(TTM) 2877.37 | ||
Enterprise Value to Revenue 1984.79 | Enterprise Value to EBITDA -13.4 | Shares Outstanding 94175994 | Shares Floating 87165533 |
Shares Outstanding 94175994 | Shares Floating 87165533 | ||
Percent Insiders 2 | Percent Institutions 114.67 |
Upturn AI SWOT
Crinetics Pharmaceuticals Inc
Company Overview
History and Background
Crinetics Pharmaceuticals Inc. is a biopharmaceutical company founded in 2008, focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. It has evolved from a research-focused entity to a clinical-stage company with a pipeline of product candidates.
Core Business Areas
- Drug Development: Crinetics is primarily focused on developing oral selective somatostatin receptor type 2 (SST2) agonists and ACTH antagonists for various endocrine disorders.
- Clinical Trials: Conducting and managing clinical trials to evaluate the safety and efficacy of their product candidates.
- Partnerships and Licensing: Establishing partnerships and licensing agreements to expand the development and commercialization of their drugs.
Leadership and Structure
The leadership team consists of the CEO, CFO, CSO, and other key executives overseeing various departments. The organizational structure is typical of a biopharmaceutical company, with research, development, clinical operations, and commercial divisions.
Top Products and Market Share
Key Offerings
- Paltusotine: An oral selective somatostatin receptor type 2 (SST2) agonist being developed for acromegaly and carcinoid syndrome. While it doesn't have market share as it's still in clinical trials, its potential market is addressing the unmet need in oral therapies for these conditions. Competitors include injectable somatostatin analogs from Novartis (Sandostatin, Pasireotide) and Chiasma (Mycapssa).
- CRN04894: An oral nonpeptide ACTH antagonist being developed for Cushing's disease and congenital adrenal hyperplasia (CAH). The market is currently addressed by surgical intervention and off-label use of various medications. Competitors include Corcept Therapeutics (Korlym) and other investigational therapies.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high R&D costs, and stringent regulatory requirements. The endocrine disease market is growing, driven by an aging population and increased awareness of hormonal disorders.
Positioning
Crinetics is positioning itself as a leader in oral therapies for endocrine diseases, aiming to provide convenient and effective alternatives to existing injectable treatments. Its competitive advantage lies in its proprietary drug discovery platform and focus on oral small molecule drugs.
Total Addressable Market (TAM)
The TAM for acromegaly, Cushing's disease, and CAH is estimated to be in the billions of dollars. Crinetics is positioned to capture a significant share of this market with its oral therapies, offering a more patient-friendly option than current treatments.
Upturn SWOT Analysis
Strengths
- Novel oral therapies for endocrine diseases
- Strong intellectual property portfolio
- Experienced management team
- Proprietary drug discovery platform
Weaknesses
- Reliance on clinical trial success
- Limited commercial infrastructure
- Cash burn rate due to R&D expenses
- Limited number of products.
Opportunities
- Expanding into new indications within endocrine diseases
- Partnering with larger pharmaceutical companies for commercialization
- Positive clinical trial results driving stock price
- Growing market for oral therapies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent expiration
Competitors and Market Share
Key Competitors
- NVS
- CRBP
- CHMA
Competitive Landscape
Crinetics faces competition from established pharmaceutical companies with approved therapies for endocrine diseases, as well as other biotechnology companies developing novel treatments. Its oral therapies offer a potential advantage over injectable treatments.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily reflected in the advancement of its clinical pipeline and partnerships.
Future Projections: Future growth depends on the successful completion of clinical trials and commercialization of its product candidates. Analyst estimates should be consulted for specific projections.
Recent Initiatives: Recent initiatives include the progression of Paltusotine and CRN04894 through clinical trials and presentations at scientific conferences.
Summary
Crinetics Pharmaceuticals is a clinical-stage biopharmaceutical company with a focus on oral therapies for endocrine disorders. Its pipeline of product candidates, particularly Paltusotine and CRN04894, hold promise but are subject to clinical trial risks. A reliance on partnerships is working well to maintain financial health. The company needs to successfully navigate regulatory hurdles and maintain its competitive advantage amidst established pharmaceutical companies.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Crinetics Pharmaceuticals Inc. SEC Filings (10-K, 10-Q)
- Crinetics Pharmaceuticals Inc. Investor Relations
- Analyst Reports
- Company website
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share is estimated and may not reflect exact figures.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Crinetics Pharmaceuticals Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2018-07-18 | Founder, President, CEO & Director Dr. R. Scott Struthers Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 437 | Website https://www.crinetics.com |
Full time employees 437 | Website https://www.crinetics.com | ||
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; SST3 Agonist program for the treatment for autosomal dominant polycystic kidney disease; and Radionetics for multiple solid-tumors, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.